Novartis Reserved Targets. If Novartis does not exercise its Option for a Lead Program with respect to any Target that is a Novartis Reserved Target, then Infinity shall not, subject to Section 2.3.2(h), file any Patent covering such Lead Program (or otherwise shall assign such Patent to Novartis), or pursue further development or commercialization of such Lead Program, including any Derivative Compounds of such Lead Program, whether alone or with a Third Party.
Appears in 4 contracts
Samples: Collaboration and Option Agreement, Collaboration and Option Agreement (Discovery Partners International Inc), Collaboration and Option Agreement (Infinity Pharmaceuticals, Inc.)
